Advanced Filters
noise

Dementia Clinical Trials

A listing of Dementia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 839 clinical trials
S Susan Donovan, BSN

Investigations of Dementia in Parkinson Disease

The purpose of this study is to use a brain imaging method called Pittsburgh B (PIB) Positron Emission Tomography (PET) and Vesicular Cholinergic Transport (VAT) PET to determine dementia subtypes in patients with Parkinson disease (PD). The ultimate goal of this project is to be able to identify individuals with …

50 years of age All Phase N/A
V Van Weehaeghe Donatienne

Amyloid PET in Patients With Mild Cognitive Impairment and Early Dementia

The National Institute on Aging together with the Alzheimer's Association (NIA-AA) recently proposed the ATN classification which is based upon the pathological processes present in Alzheimer's disease (amyloid, tau and neurodegeneration). The amyloid and tau status can be defined using cerebrospinal fluid analysis but also non-invasively using an amyloid or …

18 years of age All Phase N/A
A Arvid Rongve, Phd

ANeED Joint Effort 21: eHealth and a PPI Program in Dementia With Lewybodies (DLB)

The goal of the study is to develop predictive algorithms and digital biomarkers to capture disease fluctuations in (prodromal) dementia with lewybodies (DLB) patients and to improve treatment, diagnosis and prognosis of the study drug Ambroxol, used in the ANeED study. This project is an additional study to the ANeED …

50 - 85 years of age All Phase N/A
O Outreach Team

Longitudinal Early-onset Alzheimer's Disease Study Protocol

The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) is a non-randomized, natural history, non-treatment study designed to look at disease progression in individuals with early onset cognitive impairment. Clinical, cognitive, imaging, biomarker, and genetic characteristics will be assessed across three cohorts: (1) early onset Alzheimer's Disease (EOAD) participants, (2) early onset …

40 - 64 years of age All Phase N/A
J Jasmin Chua, MS

Neuroimaging in Healthy Aging and Senile Dementia (HASD_IND)

To identify factors that signal the transition from asymptomatic (preclinical) to symptomatic Alzheimer disease (AD).

18 years of age All Phase N/A
N NCRAD Study Coordinator

Alzheimer's Disease Genetics Study

The purpose of the Alzheimer's Disease Genetics Study is to identify the genes that are responsible for causing Alzheimer's Disease (AD). One of the ways in which the risk factor genes for late onset AD can be investigated is by identifying and collecting genetic material from families with multiple members …

years of age All Phase N/A
J Jianping Jia, Doctor

The Diagnostic Cut-off Value of Core Biomarkers of Alzheimer's Disease

The participant in this study includes Alzheimer's disease (AD including familial AD and sporadic AD) patients, amnestic mild cognitive impairment (aMCI) patients, non-AD dementia patients and cognitively normal control. The purpose of this study is to establish the best cut-off value of cerebrospinal fluid (CSF) and blood β-amyloid (Aβ) 42/40, …

55 - 75 years of age All Phase N/A
C Courtney Maa

Dominantly Inherited Alzheimer Network (DIAN)

The purpose of this study is to identify potential biomarkers that may predict the development of Alzheimer's disease in people who carry an Alzheimer's mutation.

18 years of age All Phase N/A

Cohort of Patients With Alzheimer's Disease and Their Families.

This is the pilot phase of a longitudinal observational cohort study. The study includes family clusters comprised of a patient with Alzheimer's disease, an informal caregiver and at least one first-degree relative of the patient. The family clusters will be followed-up in expert memory centers and online in order to …

18 years of age All Phase N/A
A APT Webstudy Team

Alzheimer Prevention Trials (APT) Webstudy

The goal of the Alzheimer Prevention Trials (APT) Webstudy is to accelerate enrollment for Alzheimer's disease (AD) clinical trials by identifying and tracking individuals who may be at higher risk for developing AD dementia.

50 - 85 years of age All Phase N/A

Simplify language using AI